CSL (OTCMKTS:CSLLY) Stock Rating Lowered by Zacks Research

CSL (OTCMKTS:CSLLY – Get Free Report) was downgraded by Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued on Monday,Zacks.com reports.

CSLLY has been the subject of a number of other research reports. Citigroup lowered shares of CSL from a “strong-buy” rating to a “hold” rating in a research report on Monday. Royal Bank Of Canada lowered shares of CSL from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, February 11th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold”.

Get CSL alerts:

Get Our Latest Stock Analysis on CSL

CSL Stock Performance

Shares of CSLLY opened at $17.75 on Monday. The company has a 50-day simple moving average of $24.02 and a 200-day simple moving average of $46.65. The company has a quick ratio of 1.15, a current ratio of 2.57 and a debt-to-equity ratio of 0.51. CSL has a 52 week low of $17.64 and a 52 week high of $44.86.

About CSL

(Get Free Report)

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.

Recommended Stories

• Five stocks we like better than CSL
• Navy Catalyst Ignites Odysight’s Growth Engine
• AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
• Axon Surged After Earnings and Is Still Down Over 50% From Highs
• The Event That Could Redefine Apple’s Summer Rally

Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.